Results 91 to 100 of about 4,640 (210)

Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study

BMC Cancer
This study aimed to evaluate the efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma (DLBCL).
Jing Li, Jingjing Ge, Tingting Chen, Jianghua Cao, Xiao-Hua He, Shulan Wang, Hang Yang, Yu Wang, Peng Sun, Jia-Jia Huang, Sha Liu, Zhi-Ming Li   +11 more
semanticscholar   +1 more source

A CRM1 Inhibitor Alleviates Cardiac Hypertrophy and Increases the Nuclear Distribution of NT-PGC-1α in NRVMs

Frontiers in Pharmacology, 2019
Chromosomal maintenance 1 (CRM1) inhibitors display antihypertrophic effects and control protein trafficking between the nucleus and the cytoplasm. PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1alpha) is a type of transcriptional ...
Zuheng Liu, Zuheng Liu, Haiping Tian, Haiping Tian, Haiping Tian, Jinghai Hua, Jinghai Hua, Wanqiang Cai, Wanqiang Cai, Yujia Bai, Yujia Bai, Qiong Zhan, Qiong Zhan, Wenyan Lai, Wenyan Lai, Qingchun Zeng, Qingchun Zeng, Hao Ren, Hao Ren, Dingli Xu, Dingli Xu   +20 more
doaj   +1 more source

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma

ClinicoEconomics and Outcomes Research, 2020
Jan Bassali, 1 Ian Gopal Gould, 2 James A Kaye, 3 Deirdre Mladsi, 4 Jyotsna Mehta 5 1Global Medical and Scientific Affairs Department , Karyopharm Therapeutics, Newton, MA, 02459, USA; 2Research Health Economy, RTI Health Solutions, Research Triangle ...
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J   +4 more
doaj  

Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia

Annals of Hematology
Nucleoporin 98 (NUP98) fusion oncoproteins are associated with various hematologic malignancies. Acute myeloid leukemia (AML) with NUP98-NSD1 typically co-occurs with FLT3-ITD mutations, exhibiting poor initial responses to traditional chemotherapy. This
Kun Yang, Beibei Yang, Ya-Li Zhou, Qiu-Ying Huang, Xiaolin Yin   +4 more
semanticscholar   +1 more source

Treatment of multiple myeloma with selinexor: a review

Therapeutic Advances in Hematology
Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple myeloma (MM) have been made. Nevertheless, patients with MM resistant to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a very poor outcome. Therefore, it is necessary to explore new drugs for the treatment of MM.
Qianlei Huang, Ranran Zhao, Lu Xu, Xinbao Hao, Shi Tao   +4 more
openaire   +3 more sources

Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial

European Journal of Haematology
To analyze the impact of prior therapies on outcomes with selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in 402 patients with relapsed/refractory multiple myeloma (RRMM) in the phase 3 BOSTON trial.
María-Victoria Mateos, M. Engelhardt, X. Leleu, M. G. Mesa, M. Cavo, M. Dimopoulos, Martina Bianco, Giovanni Marino Merlo, Charles la Porte, P. Richardson, P. Moreau   +10 more
semanticscholar   +1 more source

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

Haematologica
The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed.
V. González-Calle, P. Rodríguez-Otero, A. Sureda, F. de Arriba, Marta Reinoso, P. Ribas, A. González-Rodríguez, Y. González, A. Oriol, J. Martínez-López, M. González, M. Hernandez, M. Sirvent, T. Cedena, N. Puig, B. Paiva, J. Bladé, J. Lahuerta, J. San-Miguel, María-Victoria Mateos   +19 more
semanticscholar   +1 more source

Updated results from phase 2b study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma (MM) relapsing on current therapy.

Journal of Clinical Oncology
7554 Background: Selinexor is a potent selective inhibitor of nuclear export and exhibits synergistic effects when combined with other myeloma therapies.
N. Biran, D. Vesole, H. Parmar, P. Phull, K. Doucette, Jaeil Ahn, R. Feinman, J. Zenreich, Palka Anand, K. Ivanovski, Monique Pace, A. Della Pia, Bianca DeAgresta, Adolfo Aleman, Ella Rutanen, Marie Layton, Genevieve Breeze, Aimee Chappell, Susan Kumka, David S. Siegel   +19 more
semanticscholar   +1 more source

Simultaneous quantification of venetoclax, selinexor, voriconazole and fluconazole in human plasma by HPLC-MS/MS and its application in hematological malignancies. [PDF]

Front Pharmacol
Han F, Wang Y, Jian Y, Hu T, Zhu Y, Ding X, Zhang J, Wei R, Zhu H, An Z.   +9 more
europepmc   +1 more source

Responses to selinexor in multiple myeloma [PDF]

Nature Reviews Clinical Oncology, 2019
openaire   +2 more sources